27 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Article Searches
Abbott Laboratories (ABT) Q4 2023 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2024/01/24/abbott-laboratories-abt-q4-2023-earnings-call-tran/?source=iedfolrf0000001 Jan 24, 2024 - ABT earnings call for the period ending December 31, 2023.
Abbott Laboratories (ABT) 42nd Annual J.P. Morgan Healthcare Conference Call Transcript https://seekingalpha.com/article/4662007-abbott-laboratories-abt-42nd-annual-j-p-morgan-healthcare-conference-call-transcript?source=feed_sector_transcripts Jan 09, 2024 - Abbott Laboratories (NYSE:NYSE:ABT) 42nd Annual J.P.
PETQ vs. ABT: Which Stock Is the Better Value Option? https://www.zacks.com/stock/news/2194350/petq-vs-abt-which-stock-is-the-better-value-option?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2194350 Dec 06, 2023 - PETQ vs. ABT: Which Stock Is the Better Value Option?
Abbott (ABT) Advances But Underperforms Market: Key Facts https://www.zacks.com/stock/news/2197054/abbott-abt-advances-but-underperforms-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2197054 Dec 12, 2023 - Abbott (ABT) concluded the recent trading session at $106.68, signifying a +0.43% move from its prior day's close.
3 Dividend Growers Suited for Income Investors https://www.zacks.com/commentary/2207189/3-dividend-growers-suited-for-income-investors?cid=CS-ZC-FT-investment_ideas-2207189 Jan 08, 2024 - A company's ability to consistently pay and increase dividend payouts reflects a stable and healthy financial position. Who doesn't enjoy payday?
Abbott (ABT) Advances While Market Declines: Some Information for Investors https://www.zacks.com/stock/news/2207832/abbott-abt-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2207832 Jan 09, 2024 - Abbott (ABT) closed at $112.73 in the latest trading session, marking a +0.29% move from the prior day.
Seeking Clues to Abbott (ABT) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics https://www.zacks.com/stock/news/2213031/seeking-clues-to-abbott-abt-q4-earnings-a-peek-into-wall-street-projections-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2213031 Jan 19, 2024 - Beyond analysts' top -and-bottom-line estimates for Abbott (ABT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.
What's in Store for Zimmer Biomet (ZBH) in Q4 Earnings? https://www.zacks.com/stock/news/2213563/what-s-in-store-for-zimmer-biomet-zbh-in-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2213563 Jan 22, 2024 - Zimmer Biomet (ZBH) is expected to have gained from the uptake of Persona OsseoTi Keel Tibia for Cementless Knee Replacement in the fourth quarter.
Q4 Earnings Roundup: ABT, GD, KMB & More https://www.zacks.com/stock/news/2215065/q4-earnings-roundup-abt-gd-kmb-more?cid=CS-ZC-FT-ahead_of_wall_street-2215065 Jan 24, 2024 - A spot-check of early morning Q4 reports show some earnings misses and revenue beats; Tesla and others report after the close.
Insulet's (PODD) Omnipod 5 Gets CE Mark for Added Compatibility https://www.zacks.com/stock/news/2223400/insulet-s-podd-omnipod-5-gets-ce-mark-for-added-compatibility?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2223400 Feb 08, 2024 - Insulet's (PODD) tubeless automated insulin delivery system's CE mark approval with multiple CGM sensor brands is likely to serve a wider patient pool.

Pages: 123

Page 1>